Cargando...
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas
Prolactinomas are the most frequently observed pituitary adenomas and most of them respond well to conventional treatment with dopamine agonists. However, a subset of prolactinomas fails to respond to such therapies and is considered as dopamine agonist-resistant prolactinomas (DARPs). New therapeut...
Guardado en:
| Publicado en: | J Endocrinol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4760866/ https://ncbi.nlm.nih.gov/pubmed/26698564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/JOE-15-0451 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|